HK1183707A1 - Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct) - Google Patents

Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct)

Info

Publication number
HK1183707A1
HK1183707A1 HK13111067.0A HK13111067A HK1183707A1 HK 1183707 A1 HK1183707 A1 HK 1183707A1 HK 13111067 A HK13111067 A HK 13111067A HK 1183707 A1 HK1183707 A1 HK 1183707A1
Authority
HK
Hong Kong
Prior art keywords
pct
procalcitonin
prognosis
primary
infectious disease
Prior art date
Application number
HK13111067.0A
Other languages
English (en)
Chinese (zh)
Inventor
Joachim Struck
Andreas Bergmann
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39745280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1183707(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07015271A external-priority patent/EP2020603A1/en
Priority claimed from EP08152651A external-priority patent/EP2101178A1/en
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Publication of HK1183707A1 publication Critical patent/HK1183707A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK13111067.0A 2007-08-03 2013-09-27 Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct) HK1183707A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07015271A EP2020603A1 (en) 2007-08-03 2007-08-03 Method for risk stratification in stable coronary artery disease
EP08152651A EP2101178A1 (en) 2008-03-12 2008-03-12 Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes

Publications (1)

Publication Number Publication Date
HK1183707A1 true HK1183707A1 (en) 2014-01-03

Family

ID=39745280

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13111067.0A HK1183707A1 (en) 2007-08-03 2013-09-27 Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct)

Country Status (9)

Country Link
US (3) US20110136161A1 (xx)
EP (4) EP2301626B1 (xx)
JP (2) JP5059943B2 (xx)
CN (3) CN110346577A (xx)
AT (2) ATE533061T1 (xx)
DE (1) DE602008021800C5 (xx)
ES (3) ES2377112T3 (xx)
HK (1) HK1183707A1 (xx)
WO (1) WO2009019230A2 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377112T3 (es) 2007-08-03 2012-03-22 B.R.A.H.M.S Gmbh Método para el diagnóstico de una infección bacteriana
HUE046182T2 (hu) * 2009-04-14 2020-02-28 Brahms Gmbh Az antibiotikumos kezelés kozkázatának becslése elsõdlegesen nem fertõzõ betegségben szenvedõ betegekben a prokalcitonin szintjének meghatározásával
CN102449486B (zh) * 2009-06-05 2015-01-21 B.R.A.H.M.S有限公司 在患有呼吸困难的对象中检测细菌感染
DK2470910T3 (en) 2009-08-28 2017-04-03 Brahms Gmbh Procalcitonin for the prognosis of side effects
EP2320237B1 (en) 2009-10-13 2016-08-03 B.R.A.H.M.S GmbH Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack
JP5798133B2 (ja) * 2010-03-08 2015-10-21 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 不特定の愁訴を示す患者における細菌感染及び抗生物質治療の指標を診断するために用いられるプロカルシトニン
ITRM20100121A1 (it) * 2010-03-18 2011-09-19 Univ Pisa Marcatori molecolari per infezioni delle vie urinarie.
US20140051183A1 (en) * 2010-06-18 2014-02-20 B.R.A.H.M.S Gmbh Biomarkers for the prediction of incident cancer
US20130024205A1 (en) * 2011-07-18 2013-01-24 International Business Machines Corporation Dynamically updating electronic medical records and leveraging a person's path in a facility to mitgate risks
EP3367099B1 (en) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2013153177A1 (en) * 2012-04-12 2013-10-17 B.R.A.H.M.S Gmbh Prognosis of adverse events in patients with suspected chronic heart failure
EP2849729B1 (en) 2012-05-18 2018-11-14 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
ES2656897T3 (es) * 2012-08-16 2018-02-28 Critical Care Diagnostics, Inc. Procedimientos de predicción del riesgo de desarrollar hipertensión
EP2920591A4 (en) 2012-11-15 2016-10-19 Ortho Clinical Diagnostics Inc CALIBRATION ANALYZES USING REACTION TIME
CN107076746B (zh) 2014-08-14 2020-05-29 米密德诊断学有限公司 使用流形和超平面进行生物学数据的计算机分析
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US20180224464A1 (en) * 2015-06-09 2018-08-09 Osaka University Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
CN106093416B (zh) * 2016-05-18 2018-10-12 北京北方生物技术研究所有限公司 一种一步法检测降钙素原的试剂盒及其制备方法
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP3519833A4 (en) 2016-09-29 2020-06-03 MeMed Diagnostics Ltd. PROGNOSTIC AND TREATMENT METHODS
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
EP3682241B1 (en) * 2017-09-13 2022-03-30 B.R.A.H.M.S GmbH Pct and pro-adm as markers for monitoring antibiotic treatment
JP7444776B2 (ja) * 2017-12-20 2024-03-06 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
EP4256331A1 (en) * 2020-12-02 2023-10-11 Beckman Coulter, Inc. Detection of medical condition, severity, risk, and acuity using parameters
US20240219405A1 (en) 2021-04-30 2024-07-04 Roche Diagnostics Operations, Inc. Il6 marker panels for early detection of sepsis
CN117295950A (zh) 2021-04-30 2023-12-26 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的ngal标志物组
CN117597584A (zh) 2021-04-30 2024-02-23 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的esm1标志物组合
EP4330687A2 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Sflt1 marker panels for early detection of sepsis
US20240219404A1 (en) 2021-04-30 2024-07-04 Roche Diagnostics Operations, Inc. Igfbp7 marker panels for early detection of sepsis
JP2024514676A (ja) 2021-04-30 2024-04-02 エフ． ホフマン－ラ ロシュ アーゲー 敗血症の早期検出用のｐｃｔマーカーパネル
EP4330682A2 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Presepsin marker panels for early detection of sepsis
CN117280218A (zh) 2021-04-30 2023-12-22 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的strem1标志物组
CN117203528A (zh) 2021-04-30 2023-12-08 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的gdf15标志物组
WO2023052446A1 (en) 2021-09-29 2023-04-06 F. Hoffmann-La Roche Ag Mr-proadm marker panels for early detection of sepsis
WO2023156655A1 (en) 2022-02-21 2023-08-24 F. Hoffmann-La Roche Ag Dll1 marker panels for early detection of sepsis
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227454C1 (de) 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US6147688A (en) 1993-06-28 2000-11-14 Athena Design Systems, Inc. Method and apparatus for defining and selectively repeating unit image cells
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
US6156521A (en) 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
DE19903336C2 (de) 1999-01-28 2000-12-14 Brahms Diagnostica Gmbh Gebrauchsfertige Kalibratoren für die Bestimmung von Procalcitonin
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
JP3806694B2 (ja) * 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2006527190A (ja) 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
US20050170443A1 (en) * 2003-10-03 2005-08-04 Scantibodies Laboratory, Inc. Methods and use of binding components for improving assay specificity
CA2485722A1 (en) 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
EP1564558B1 (de) 2004-02-13 2005-12-07 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens
US20060024744A1 (en) 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
DE102004041659A1 (de) 2004-08-27 2006-03-02 Institut Virion/Serion Gmbh Testvorrichtung für die in vitro Diagnostik von Multianalyt-Tests und deren Verwendung
CA2612450C (en) 2005-06-28 2014-04-29 Zbx Corporation Membrane array and analytical device
DE102005034174A1 (de) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
AU2006299417A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
CN1800384A (zh) * 2005-11-08 2006-07-12 浙江大学 降钙素原的制备方法
EP2005168A4 (en) 2006-03-09 2009-05-20 Biosite Inc METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA
DE102006046996A1 (de) 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
EP2020603A1 (en) 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Method for risk stratification in stable coronary artery disease
ES2377112T3 (es) 2007-08-03 2012-03-22 B.R.A.H.M.S Gmbh Método para el diagnóstico de una infección bacteriana
DE102008037108A1 (de) 2008-08-08 2010-02-11 Samson Aktiengesellschaft System zum Stellen eines Stellorgans
EP2320237B1 (en) * 2009-10-13 2016-08-03 B.R.A.H.M.S GmbH Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack
US20110263438A1 (en) 2010-04-22 2011-10-27 Mehmet Ali Soylemez Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin

Also Published As

Publication number Publication date
EP2174143B1 (en) 2011-06-22
CN103123359B (zh) 2015-07-29
DE602008021800C5 (de) 2022-05-05
US10456364B2 (en) 2019-10-29
JP5185460B2 (ja) 2013-04-17
EP2293076B1 (en) 2012-12-19
JP5059943B2 (ja) 2012-10-31
EP2293076A3 (en) 2011-03-30
EP2301626A2 (en) 2011-03-30
ES2401703T3 (es) 2013-04-23
CN103123359A (zh) 2013-05-29
EP2293076A2 (en) 2011-03-09
US20110152170A1 (en) 2011-06-23
JP2012237760A (ja) 2012-12-06
CN101790687A (zh) 2010-07-28
EP2293078B1 (en) 2011-11-09
WO2009019230A3 (en) 2009-04-23
EP2174143A2 (en) 2010-04-14
ATE533061T1 (de) 2011-11-15
US11241395B2 (en) 2022-02-08
US20110136161A1 (en) 2011-06-09
CN110346577A (zh) 2019-10-18
ES2403310T3 (es) 2013-05-17
JP2010536012A (ja) 2010-11-25
ES2377112T3 (es) 2012-03-22
EP2301626A3 (en) 2011-11-16
ATE514091T1 (de) 2011-07-15
EP2293078A3 (en) 2011-04-06
EP2301626B1 (en) 2013-01-16
WO2009019230A4 (en) 2009-06-25
WO2009019230A2 (en) 2009-02-12
EP2293078A2 (en) 2011-03-09
US20190224135A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
HK1183707A1 (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct)
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
EP2596132A4 (en) METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
WO2006091412A3 (en) Adamts-7 as a biomarker for cancers of epithelial origin
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
ATE520032T1 (de) Differentielle cytokinexpression bei einer menschlichen krebserkrankung
CA2863393A1 (en) A multi-biomarker-based outcome risk stratification model for pediatric septic shock
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
MY179250A (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
BRPI1007637A2 (pt) método para a detecção e/ou a tipificação e/ou a quantificação da presença de um papilomavírus humano (hpv) do tipo 18, 52, 59, 39, 51, 56, 66, 16, 45, 58, 31, 33 e 35 em uma amostra biológica primers e sondas, kit de diagnóstico e uso do kit de diagnóstico
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina
BR112013015394A2 (pt) método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto
Fatemi-Naeini et al. Mycosis Fungoides: Epidemiology in Isfahan, Iran
UA52774U (ru) Способ диагностики состояния шейки матки в женщин, инфицированных вирусом папилломы человека
PL422611A1 (pl) Sposób wykrywania uszkodzenia nerek pojawiającego się u chorych z cukrzycą
Imler Re: Marks SL, Wegelin JA, Bourgeois, JA, Perkins J. Anxiety disorders in rural primary care: use of the MINI to estimate prevalence in clinic patients. J Health Care Poor Underserved. 2010 May; 21 (2): 680–90
UA35984U (ru) Способ дифференциальной диагностики ранних стадий остеоартрозов больших суставов
Volodchenko Treatment of Struma in Elderly People
UA61535U (ru) Способ прогнозирования возможности развития нарушений консолидации переломов костей